XBIO Xenetic Biosciences Inc.
NewsSee all news
-
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November
-
Xenetic Biosciences, Inc. Provides Business Outlook
Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- Company ramps up activities to execute XCART's preclinical and regulatory strategy -- Cash runway expected to fund Company through preclinical advancements towards IND filing -FRAMINGHAM, MA / ACCESSWIRE / November
-
Xenetic Biosciences, Inc. Provides Business Outlook
Recent completion of acquisition of innovative CAR T technology platform (XCART) has the potential to drive significant value for shareholders Management working with KOLs and subject matter experts to formalize XCART